Theriva Biologics, Inc. focuses on developing innovative therapies for cancer and other serious diseases, leveraging its proprietary platform for biologics. The company aims to differentiate itself through its targeted approach to immunotherapy, particularly in the treatment of solid tumors.
Business Overview
Theriva Biologics generates revenue primarily through the commercialization of its biologic therapies. The company has a competitive advantage due to its proprietary drug delivery systems that enhance the efficacy of treatments, allowing for targeted delivery to tumor sites, which may lead to better patient outcomes.
Clinical trial results for lead product candidates
Regulatory approvals from the FDA or EMA
Partnership announcements with larger pharmaceutical companies
Market adoption rates of therapies post-launch
Risk Factors
Regulatory changes impacting drug approval processes
Technological disruption in drug development methodologies
Emergence of new therapies that could outperform current offerings
Increased competition from established biotech firms
High cash burn rate leading to potential liquidity issues
Dependence on successful fundraising to support ongoing R&D
Macro Sensitivity
low - The biotechnology sector is generally less sensitive to economic cycles as demand for healthcare remains relatively stable regardless of economic conditions.
Moderate - Rising interest rates can increase the cost of capital for funding R&D, potentially delaying product development timelines.
minimal - The company has a manageable debt-to-equity ratio of 0.24, indicating limited reliance on credit.
Profile
growth - Investors seeking high-risk, high-reward opportunities in the biotech sector.
high - The stock has experienced significant price fluctuations, as evidenced by a 1-year return of -42.4%.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
